Immunotherapies News and Research RSS Feed - Immunotherapies News and Research

CGT, CTM CRC collaborate to test patented scaffold technology for commercial scale cell expansion systems

CGT, CTM CRC collaborate to test patented scaffold technology for commercial scale cell expansion systems

The Cell and Gene Therapy Catapult and the CRC for Cell Therapy Manufacturing, the Australian centre for translation of cell therapy technologies, today announce a project to test at scale CTM CRC’s patented scaffold technology. [More]
Researchers find ways to switch on Natural Killer cells to combat cancer

Researchers find ways to switch on Natural Killer cells to combat cancer

Our bodies are constantly and successfully fighting off the development of cells that lead to tumours - but when there is disruption to this process cancer is free to develop. [More]
Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Only 12% of kidney cancer patients with advanced disease survive five years after their initial treatment. In a Roswell Park Cancer Institute-led study, scientists report that some patients with advanced kidney cancer who continued to receive a novel immunotherapy drug after their disease progressed saw clinical benefit. [More]
Radiation-immunotherapy combination can help treat melanoma

Radiation-immunotherapy combination can help treat melanoma

Combining radiation treatments with a new generation of immunotherapies is showing promise as a one-two-punch against melanoma, Loyola Medicine researchers report in a review article. [More]
NSCLC MAGE-A3 immunotherapy development halted

NSCLC MAGE-A3 immunotherapy development halted

Disease-free survival is not prolonged with adjuvant MAGE-A3 immunotherapy in patients with surgically resected non-small-cell lung cancer, according to a placebo-controlled trial. [More]
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [More]
Penn researchers report results of CAR therapy trial in brain cancer patients

Penn researchers report results of CAR therapy trial in brain cancer patients

Immune cells engineered to seek out and attack a type of deadly brain cancer known as glioblastoma (GBM) were found to have an acceptable safety profile and successfully migrate to and infiltrate tumors, researchers from Penn Medicine and Harvard University reported at the AACR Annual Meeting 2016. [More]
Distribution of c-Myc protein during asymmetric cell division influences fate, roles of activated T cells

Distribution of c-Myc protein during asymmetric cell division influences fate, roles of activated T cells

The fates of immune cells can be decided at the initial division of a cell. Researchers at St. Jude Children's Research Hospital have discovered that the production of daughter cells with different roles in the immune system is driven by the lopsided distribution of the signaling protein c-Myc. Nudging c-Myc in one direction or the other could make vaccines more effective or advance immunotherapies for cancer treatment. The research appears online today in the scientific journal Nature. [More]
AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will report new clinical trial and scientific data from their industry-leading lung cancer franchise of marketed and pipeline medicines at the European Lung Cancer Conference in Geneva, Switzerland, 13 -16 April 2016. [More]
Rituximab shows second-line promise in autoimmune limbic encephalitis

Rituximab shows second-line promise in autoimmune limbic encephalitis

Rituximab is an effective and well-tolerated second-line treatment for patients with autoimmune limbic encephalitis, suggests research. [More]
Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center. [More]
Oral Salmonella-based vaccine could prevent Type 1 diabetes

Oral Salmonella-based vaccine could prevent Type 1 diabetes

A combined vaccine therapy including live Salmonella is a safe and effective way to prevent diabetes in mice and may point to future human therapies, a new study finds. The results will be on Sunday, April 3, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston. [More]
Targeted therapies suppress T cell activity that could actually help fight tumors

Targeted therapies suppress T cell activity that could actually help fight tumors

In many cases, targeted therapies for cancer are preferred as treatments over chemotherapy and surgery because they attack and kill cancer cells with specific tumor-promoting mutations while sparing healthy, normal cells that do not express these mutations. [More]
Inhibiting cholesterol esterification can potentiate antitumor activity of killer T cells

Inhibiting cholesterol esterification can potentiate antitumor activity of killer T cells

As key players in the immune system, T cells provide tumor surveillance and have direct antitumor effects. However, tumors can escape T-cell attack through various mechanisms in the tumor microenvironment. Reactivating the antitumor effects of T cells has shown great clinical benefits in treating various cancers. [More]
HIV drug could delay drug resistance, making skin cancer treatment effective for longer time

HIV drug could delay drug resistance, making skin cancer treatment effective for longer time

An HIV drug could stop one of the early changes in skin cancer cells that leads to them becoming resistant to treatment, according to a Cancer Research UK-funded study published in Cancer Cell today [More]
Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

A study of obesity and related metabolic changes on bladder cancer incidence and deaths, and a plan to use stem cells to grow novel urinary tubes are among 10 research projects awarded funding by the Johns Hopkins Greenberg Bladder Cancer Institute. [More]
Means to target all tumor cells with one treatment uncovered

Means to target all tumor cells with one treatment uncovered

Research sponsored by Cancer Research UK has identified mutations common to all tumour cells. Immunotherapies specific for these mutations could deliver chemotherapeutic agents to all tumour cells and destroy them. [More]
New drug combination shows promise for patients with non-small cell lung cancer

New drug combination shows promise for patients with non-small cell lung cancer

Lung cancer is the most common cause of cancer-related death in the United States resulting in more than 158,000 deaths each year. With a 5-year survival rate at only 18 percent, the development of new and improved treatment options is needed. [More]
New optogenetic technology could turn on immune cells to attack melanoma tumors

New optogenetic technology could turn on immune cells to attack melanoma tumors

A new optogenetic technology developed at UMass Medical School, called optogenetic immunomodulation, is capable of turning on immune cells to attack melanoma tumors in mice. Using near-infrared light, UMMS researchers have shown they can selectively activate an immune response by controlling the flow of calcium ions into the cell. This breakthrough could lead to less invasive, and more controlled and selective, immunotherapies for cancer treatment. [More]
Wistar researchers find potential way for using STAT3 inhibitors to stop cancer progression

Wistar researchers find potential way for using STAT3 inhibitors to stop cancer progression

Imagine developing a drug designed to inhibit a protein that helps cancer cells proliferate and survive only to find that the drug does not perform very well in the clinic. This was the dilemma faced by scientists researching inhibitors of signal transducer and activator of transcription (STAT3), a protein that controls transcription by the STAT3 gene. [More]
Advertisement
Advertisement